Skip to main content
. 2015 Mar 7;48(1):153–161. doi: 10.4143/crt.2014.183

Fig. 4.

Fig. 4.

Subgroup analysis of progression-free survival (PFS) between responders and non-responders of chromogranin A according to Response Evaluation Criteria in Solid Tumors criteria (A), tumor grade (B), and primary sites (C). GEP-NETs, gastroenteropancreatic neuroendocrine tumors.